Impact of obesity on the efficacy of different biologic agents in inflammatory diseases: A systematic review and meta-analysis

• Published in: Joint, bone, spine : revue du rhumatisme Vol. 86; no. 2; pp. 173 - 183
• Main Authors: Shan, Juan, Zhang, Jiabi
• Format: Journal Article
• Language: English
• Published: France Elsevier Masson SAS 01.03.2019
• Subjects: Abatacept; Abatacept - therapeutic use; Anti-TNF agents; Antibodies, Monoclonal, Humanized - therapeutic use; Antirheumatic Agents - therapeutic use; Arthritis, Psoriatic - drug therapy; Arthritis, Psoriatic - epidemiology; Arthritis, Rheumatoid - drug therapy; Arthritis, Rheumatoid - epidemiology; BDMARDs; Biological Products - pharmacology; Biological Products - therapeutic use; Comorbidity; Crohn Disease - drug therapy; Crohn Disease - epidemiology; Female; Humans; Inflammation - drug therapy; Inflammation - epidemiology; Inflammatory diseases; Male; Obesity; Obesity - diagnosis; Obesity - epidemiology; Prognosis; Risk Assessment; Spondylitis, Ankylosing - drug therapy; Spondylitis, Ankylosing - epidemiology; Tocilizumab; Treatment Outcome; Obesity; Anti-TNF agents; BDMARDs; Abatacept; Tocilizumab; Inflammatory diseases

•Meta-analysis shows that the odds of reaching a good response and achieving remission were lower in obese patients who were treated with anti-TNF agents.•Meta-analysis suggests obesity does not affect the response to abatacept or tocilizumab in RA patients.•Obesity negatively influences improvement...